Cargando…
Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
The aim of this study was to assess the annualized changes in body composition, including skeletal muscle, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) before, during, and after sorafenib treatment in patients with hepatocellular carcinoma (HCC). This retrospective study eval...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407859/ https://www.ncbi.nlm.nih.gov/pubmed/32635536 http://dx.doi.org/10.3390/cancers12071795 |
_version_ | 1783567702217981952 |
---|---|
author | Imai, Kenji Takai, Koji Miwa, Takao Taguchi, Daisuke Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito |
author_facet | Imai, Kenji Takai, Koji Miwa, Takao Taguchi, Daisuke Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito |
author_sort | Imai, Kenji |
collection | PubMed |
description | The aim of this study was to assess the annualized changes in body composition, including skeletal muscle, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) before, during, and after sorafenib treatment in patients with hepatocellular carcinoma (HCC). This retrospective study evaluated 61 HCC patients treated with sorafenib. Annualized changes (Δ; cm(2)/m(2)/year) in skeletal muscle index (SMI), SAT index (SATI), and VAT index (VATI), which were defined as the cross-sectional areas (cm(2)) of those areas on computed tomography normalized by the square of one’s height (m(2)), before ((pre)), during ((during)), and after ((post)) sorafenib treatment, were calculated. Patients within the 20th percentile cutoffs for these indices were classified into the rapid depletion group and the effects of these values on survival were analyzed using the Kaplan-Meier analysis and Cox proportional-hazards model. Annualized depletion rates of SMI (ΔSMI(pre): −3.5, ΔSMI(during): −3.5, ΔSMI(post): −8.0) and VATI (ΔVATI(pre): −3.2, ΔVATI(during): −2.8, ΔVATI(post): −15.1) accelerated after the cancellation of sorafenib, whereas that of SATI (ΔSATI(pre): −4.8, ΔSATI(during); −7.6, ΔSATI(post); −8.0) had already accelerated during sorafenib treatment. Patients with rapid depletion of ΔSATI(during) experienced significantly worse survival rates (p < 0.001), and it was an independent predictor of survival (p = 0.009), together with therapeutic effect (p < 0.001). Rapid depletion of SAT during sorafenib treatment can be used to predict survival in patients with HCC. |
format | Online Article Text |
id | pubmed-7407859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74078592020-08-12 Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma Imai, Kenji Takai, Koji Miwa, Takao Taguchi, Daisuke Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito Cancers (Basel) Article The aim of this study was to assess the annualized changes in body composition, including skeletal muscle, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) before, during, and after sorafenib treatment in patients with hepatocellular carcinoma (HCC). This retrospective study evaluated 61 HCC patients treated with sorafenib. Annualized changes (Δ; cm(2)/m(2)/year) in skeletal muscle index (SMI), SAT index (SATI), and VAT index (VATI), which were defined as the cross-sectional areas (cm(2)) of those areas on computed tomography normalized by the square of one’s height (m(2)), before ((pre)), during ((during)), and after ((post)) sorafenib treatment, were calculated. Patients within the 20th percentile cutoffs for these indices were classified into the rapid depletion group and the effects of these values on survival were analyzed using the Kaplan-Meier analysis and Cox proportional-hazards model. Annualized depletion rates of SMI (ΔSMI(pre): −3.5, ΔSMI(during): −3.5, ΔSMI(post): −8.0) and VATI (ΔVATI(pre): −3.2, ΔVATI(during): −2.8, ΔVATI(post): −15.1) accelerated after the cancellation of sorafenib, whereas that of SATI (ΔSATI(pre): −4.8, ΔSATI(during); −7.6, ΔSATI(post); −8.0) had already accelerated during sorafenib treatment. Patients with rapid depletion of ΔSATI(during) experienced significantly worse survival rates (p < 0.001), and it was an independent predictor of survival (p = 0.009), together with therapeutic effect (p < 0.001). Rapid depletion of SAT during sorafenib treatment can be used to predict survival in patients with HCC. MDPI 2020-07-04 /pmc/articles/PMC7407859/ /pubmed/32635536 http://dx.doi.org/10.3390/cancers12071795 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Imai, Kenji Takai, Koji Miwa, Takao Taguchi, Daisuke Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title | Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title_full | Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title_fullStr | Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title_full_unstemmed | Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title_short | Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma |
title_sort | rapid depletion of subcutaneous adipose tissue during sorafenib treatment predicts poor survival in patients with hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407859/ https://www.ncbi.nlm.nih.gov/pubmed/32635536 http://dx.doi.org/10.3390/cancers12071795 |
work_keys_str_mv | AT imaikenji rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT takaikoji rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT miwatakao rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT taguchidaisuke rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT hanaitatsunori rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT suetsuguatsushi rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT shirakimakoto rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma AT shimizumasahito rapiddepletionofsubcutaneousadiposetissueduringsorafenibtreatmentpredictspoorsurvivalinpatientswithhepatocellularcarcinoma |